Xenetic Biosciences, Inc.

NasdaqCM:XBIO Stock Report

Market Cap: US$6.2m

Xenetic Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of XBIO?
Owner TypeNumber of SharesOwnership Percentage
Institutions58,5313.8%
Public Companies105,5946.85%
Individual Insiders112,2417.28%
Private Companies147,5009.56%
General Public1,118,27372.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 16 shareholders own 27.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.56%
CLS Therapeutics, Inc.
147,500US$595.9k0%no data
6.85%
Public Joint-Stock Company "Pharmsynthez"
105,594US$426.6k0%no data
4.44%
Dmitry Genkin
68,464US$276.6k0%no data
2.42%
Alexey Vinogradov
37,358US$150.9k0%no data
1.13%
Sachetta, LLC
17,371US$70.2k0%0.03%
1.03%
Renaissance Technologies LLC
15,850US$64.0k0%no data
0.77%
Geode Capital Management, LLC
11,889US$48.0k-0.83%no data
0.64%
The Vanguard Group, Inc.
9,797US$39.6k0%no data
0.39%
Michael Maguire
6,002US$24.2k0%no data
0.18%
Royal Bank of Canada Trust Company (Bahamas) Limited, Asset Management Arm
2,700US$10.9k0%no data
0.045%
Tower Research Capital Europe Limited
692US$2.8k0%no data
0.027%
Jeffrey Eisenberg
417US$1.7k0%no data
0.013%
JPMorgan Chase & Co, Brokerage and Securities Investments
200US$808.10%no data
0.0019%
Bank of America Corporation, Asset Management Arm
29US$117.1164%no data
0.00013%
Darwin Wealth Management, LLC
2US$8.10%no data
0.00006%
Morgan Stanley, Investment Banking and Brokerage Investments
1US$3.70%no data